Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have earned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $51.00.

Several equities research analysts have recently issued reports on the stock. Barclays reduced their price objective on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 19th. Needham & Company LLC cut their target price on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Piper Sandler reissued a “neutral” rating and set a $43.00 price objective (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday, August 7th. Finally, Weiss Ratings lowered Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock traded up $0.17 during trading hours on Monday, hitting $27.29. The company’s stock had a trading volume of 102,059 shares, compared to its average volume of 509,012. The company has a market cap of $888.29 million, a PE ratio of 22.00 and a beta of 0.73. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03. The business has a 50 day moving average price of $33.67 and a two-hundred day moving average price of $35.70. Collegium Pharmaceutical has a 12-month low of $25.47 and a 12-month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The firm had revenue of $199.88 million during the quarter, compared to analysts’ expectations of $199.62 million. During the same quarter last year, the business posted $1.68 earnings per share. The firm’s revenue was up 6.3% on a year-over-year basis. Analysts expect that Collegium Pharmaceutical will post 6.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in COLL. California State Teachers Retirement System increased its stake in Collegium Pharmaceutical by 5,165.8% in the 2nd quarter. California State Teachers Retirement System now owns 1,550,410 shares of the specialty pharmaceutical company’s stock worth $56,125,000 after acquiring an additional 1,520,967 shares during the last quarter. Hsbc Holdings PLC boosted its position in shares of Collegium Pharmaceutical by 43.5% during the 2nd quarter. Hsbc Holdings PLC now owns 39,609 shares of the specialty pharmaceutical company’s stock valued at $1,424,000 after acquiring an additional 12,015 shares during the last quarter. Empowered Funds LLC purchased a new position in shares of Collegium Pharmaceutical in the second quarter valued at $2,045,000. United Capital Financial Advisors LLC purchased a new position in shares of Collegium Pharmaceutical in the second quarter valued at $465,000. Finally, Jefferies Financial Group Inc. bought a new stake in Collegium Pharmaceutical in the second quarter worth $992,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.